Publications by authors named "Fueyo J"
Article Synopsis
- There are major gaps in understanding how immunotherapy affects the nervous system in children, mostly due to a lack of research focused on pediatric patients.
- Identifying and grading the neurotoxic effects of immunotherapy in children is complicated by inconsistent terminology and the variation in treatment responses based on factors like disease type and therapy methods.
- The review emphasizes the need for further research into the specific neurotoxic effects of various immunotherapy approaches in pediatric oncology, as well as the unique challenges presented by combining therapies.
Pediatric brain tumors are the most common solid tumors in children. Even to date, with the advances in multimodality therapeutic management, survival outcomes remain dismal in some types of tumors, such as pediatric-type diffuse high-grade gliomas or central nervous system embryonal tumors. Failure to understand the complex molecular heterogeneity and the elusive tumor and microenvironment interplay continues to undermine therapeutic efficacy.
View Article and Find Full Text PDFArticle Synopsis
- The text refers to a correction made to a published article identified by its DOI (Digital Object Identifier) 10.1016/j.omton.2024.200787.* -
- This implies that there were errors or inaccuracies in the original article that needed to be addressed.* -
- The correction ensures that readers have access to the right information for accuracy in research or study.*
In this work, a workflow has been developed for the generation of surrogate metamodels to predict and evaluate failure with a confidence above 95 % in initial service conditions of high-performance cylindrical vessels manufactured in composites by Roll Wrapping technology. Currently, there is no specific testing standardization for this type of vessel and to fill this gap probabilistic numerical models were developed, performed by the Finite Element Method, fed with the material characteristics obtained experimentally by 2D digital image correlation from flat specimens. From the initial numerical model, a surrogate metamodel was generated by stochastic approximations.
View Article and Find Full Text PDFArticle Synopsis
- Glioblastoma has a low 5-year survival rate of 6.8%, prompting research into new treatments like the engineered adenovirus Delta-24-RGDOX, which interacts with immune systems.* -
- This study explores the link between gut microbiota and the effectiveness of oncolytic viroimmunotherapy, discovering that changes in gut bacteria were associated with better survival rates in treated mice.* -
- Results indicate that depleting CD4 T cells led to altered gut microbiota, reduced survival, and decreased effectiveness of the therapy, highlighting the importance of gut health in cancer treatment outcomes.*
Article Synopsis
- * The methods for using OVs in cancer vaccination often require genetic modifications for each specific target, which can be inefficient for rare antigens.
- * A recent study introduced a new PeptiCRAd vaccination platform that allows for the identification of immunogenic TAAs in mesothelioma and coats oncolytic adenovirus particles with them, creating a streamlined and personalized cancer vaccine without the need for extensive genetic engineering.
Article Synopsis
- Pediatric high-grade gliomas (pHGGs), particularly diffuse midline gliomas (DMGs), are highly aggressive tumors with low survival rates, yet the combination of Delta-24-RGD and ONC201 has shown potential for enhanced treatment efficacy.
- In laboratory and mouse model studies, the combination treatment did not alter virus replication but demonstrated a synergistic or additive cytotoxic effect, leading to increased DNA damage and metabolic disruptions in tumor cells.
- Additionally, the combination treatment improved survival rates in mice models and led to a shift in the tumor microenvironment towards a more proinflammatory state, indicating a stronger immune response against the tumors.
Oncolytic viruses are a promising treatment for patients with high-grade gliomas, but neutralizing antibodies can limit their efficacy in patients with prior virus exposure or upon repeated virus injections. Data from a previous clinical trial using the oncolytic adenovirus Delta-24-RGD showed that generation of anti-viral neutralizing antibodies may affect the long-term survival of glioma patients. Past studies have examined the effects of neutralizing antibodies during systemic virus injections, but largely overlooked their impact during local virus injections into the brain.
View Article and Find Full Text PDFArticle Synopsis
- * Understanding the molecular and cellular mechanisms behind resistance to immunotherapy is essential for developing better treatments, focusing on the innate immune response to boost overall effectiveness.
- * This review discusses various approaches, such as activating immune receptors and enhancing immune cells, which may improve GBM treatment outcomes based on both preclinical and clinical research findings.
Article Synopsis
- Researchers developed a rabbit model to study endovascular selective intra-arterial (ESIA) infusions for treating glioblastoma using human GBM cell lines to implant tumors.
- The model involved immunosuppressing rabbits and performing microcatheter infusions of mesenchymal stem cells loaded with an oncolytic adenovirus (MSC-D24), demonstrating the approach's safety and efficacy.
- Results showed successful tumor formation in the rabbits and that the MSC-D24 treatment effectively targeted the implanted tumors, providing a relevant method for testing new cancer therapies.
Article Synopsis
- The study investigates how the oncolytic adenovirus Delta-24-RGDOX can enhance the effectiveness of adoptive cell therapies, especially in treating solid tumors where cancer cells can be diverse and the surrounding environment suppresses immune responses.
- Using mouse models with B16 melanoma, the researchers found that administering Delta-24-RGDOX after injecting tumor-associated antigen (TAA)-targeting T cells led to improved tumor responses and increased survival rates.
- This approach not only activated the tumor microenvironment but also boosted the immune response by increasing the density of specific immune cells, ultimately enhancing systemic antitumor immunity and reducing the chances of tumor relapse.
Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab in recurrent glioblastoma, first in a dose-escalation and then in a dose-expansion phase, in 49 patients. The primary endpoints were overall safety and objective response rate.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers utilized various analysis methods, including RNA sequencing and flow cytometry, to assess the impact of the oncolytic virus Delta-24-RGDOX and its combination with IDO inhibitors in animal models of gliomas.
- * Results indicated that the combination therapy led to increased CD8 T cell presence while reducing immunosuppressive cell populations, ultimately suggesting a strategy to boost the immune response against tumors.
Article Synopsis
- - Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor prognosis, with less than 1-year median survival; studies on oncolytic viral therapy like DNX-2401 for DIPG are limited.
- - A single-center study administered DNX-2401 to 12 newly diagnosed DIPG patients to assess safety, adverse events, and effectiveness, with treatments including a virus infusion and radiotherapy.
- - Results showed that DNX-2401 led to tumor size reduction in 9 patients and a median survival of 17.8 months, with some patients experiencing changes in their tumor microenvironment and immune response.
Remission of liquid tumors and SARS-CoV-2 infection: A literature review.
Mol Ther Oncolytics
September 2022
Article Synopsis
- The COVID-19 pandemic has created a significant challenge for cancer patients, as the virus and cancer treatments weaken the immune system, leading to more severe symptoms and poorer outcomes.
- Some clinical cases reveal that certain viruses, including SARS-CoV-2, may induce remission in patients with liquid tumors, suggesting a potential therapeutic avenue.
- Oncolytic virotherapy, which uses viruses to target cancer, shows promise as a form of cancer immunotherapy, potentially triggering local inflammation that could create a systemic effect to combat cancer beyond just the treated area.
A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.
Am Soc Clin Oncol Educ Book
April 2022
Article Synopsis
- Glioblastoma is the most common and challenging primary malignant brain tumor, with a pressing need for new treatments despite advancements in understanding its genetics.
- The blood-brain barrier poses a significant challenge, preventing most drugs from effectively reaching tumor cells, which often leads to failures in clinical trials for neuro-oncology.
- Utilizing window-of-opportunity clinical trial designs can help assess new therapies early on by addressing access issues to tumor tissue and guiding the development of various drug types, including small molecules and immunotherapies.
Article Synopsis
- DIPGs are really tough brain tumors in kids, and doctors are looking for better treatments because current options aren’t working well.
- A new treatment called Delta-24-ACT uses a special virus to help the immune system fight these tumors, showing promise in mice by making them live longer.
- This treatment is safe for the mice and helps their immune systems become stronger against the tumors, suggesting it could be a good option for kids with DIPG in the future.
Article Synopsis
- The study investigates the safety and efficacy of oncolytic adenovirus Delta24-RGD, delivered via convection enhanced delivery (CED) in patients with recurrent glioblastoma.
- Out of 20 patients, 19 received treatment with Delta24-RGD, which was found to be safe, with some experiencing positive tumor responses, including one patient with complete regression lasting over 8 years.
- Results indicated that CED led to a local inflammatory reaction, increased immune response marked by rising cytokine levels, and immune cell proliferation, with no viral shedding detected in excreta.
Dowel-type fasteners are one of the most used type of connections in timber joints. Its design follows the equations included in the Eurocode 5. The problem with these equations is that they do not adequately contemplate the resistive capacity increase of these joints, when using configurations which provoke the so-called rope effect.
View Article and Find Full Text PDFArticle Synopsis
- * Delta-24-ACT is a modified oncolytic adenovirus that targets cancer cells and boosts immune responses, showing promise in fighting osteosarcoma.
- * Research demonstrated that Delta-24-ACT effectively killed osteosarcoma cells in the lab and improved survival rates in mice without causing toxicity, supporting its potential as a new treatment for both local and metastatic cases.
Article Synopsis
- The text addresses and corrects misinformation found in article PMC7470213.
- It likely provides clarifications or amendments to previously stated research findings.
- The goal is to ensure accuracy and reliability in the published research material.
Article Synopsis
- The study investigates the use of bone marrow-derived human mesenchymal stem cells (BM-hMSCs) from glioma patients who have undergone marrow-toxic chemotherapy as carriers for an oncolytic virus called Delta-24-RGD, which targets and kills glioma cells.
- Five patients with recurrent malignant glioma were enrolled, and their BM-hMSCs were cultured and shown to have similar properties to those from healthy donors, including the ability to differentiate into different cell types.
- The findings indicate that the patient-derived BM-hMSCs effectively delivered Delta-24-RGD in preclinical models, significantly improving survival rates in mice with gliomas, suggesting potential for clinical application.
Article Synopsis
- Glioblastoma (GBM) is a tough brain tumor with a suppressive environment, but the new oncolytic virus Delta-24-ACT shows promise as a treatment, especially when paired with immune checkpoint inhibitors (ICIs).
- Laboratory tests confirmed that Delta-24-ACT effectively infected and killed glioma cells, prolonged survival in mouse models, and modified the tumor environment to promote immune cell activity.
- Combining Delta-24-ACT with anti-PD-L1 therapy led to significantly better results in tumor-bearing mice than using either treatment alone, suggesting a more effective strategy for attacking GBM.
Article Synopsis
- Oncolytic adenoviruses show promise for treating solid tumors like glioblastoma (GBM), but existing animal models are limited due to species selectivity, necessitating a new approach.
- Researchers developed an intracranial glioma model using Syrian hamsters that allows for viral replication and immune response assessment, addressing gaps in current models.
- Findings revealed that the virus Delta-24-RGD effectively kills tumor cells, increases T-cell infiltration in tumors, and significantly improves survival in treated hamsters compared to controls, suggesting the model's potential for future clinical applications.